Business Wire

Cargill and Hafnia Launch Seascale Energy to Accelerate the Transformation of Marine Fuel Procurement Services

Share

The new joint venture will efficiently meet customer needs worldwide, ensuring reliable access to high-quality marine fuel at competitive prices

Cargill’s Ocean Transportation business and leading tanker shipping company, Hafnia, have joined forces to launch Seascale Energy, a joint venture, combining Cargill’s existing bunker business Pure Marine Fuels and Hafnia’s Bunker Alliance. By combining the strengths of two global players, Seascale Energy aims to set a new standard for marine fuel procurement by delivering considerable cost efficiencies, transparency, and access to sustainable fuel innovations.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250219375030/en/

By consolidating bunker purchasing volumes, the venture will secure even more competitive pricing and terms while providing tailored procurement solutions to meet its customers' diverse needs. It will also offer an expanded global port network, giving customers a consistent, high-quality fuel supply worldwide.

Cargill and Hafnia’s global reach and trading strength, coupled with maritime operational excellence, create a first-class solution for bunker management,” said Jan Dieleman, President of Cargill’s Ocean Transportation business. “Our vision is to lead the energy transition in shipping, unlocking value for our stakeholders while addressing industry challenges around transparency, quality, and decarbonization. Together, we are shaping a more sustainable future for marine fuel procurement.”

The joint venture offers shipowners and charterers improved transparency and scale, enabling them to secure competitive deals and benchmark performance. Tailored procurement services will reduce internal costs, freeing resources for customers to focus on their core operations.

Seascale Energy represents our shared vision to simplify and innovate the increasing complexities in the bunkering segment,” said Hafnia CEO Mikael Skov. “As one of the largest services of its kind, led by two large-scale fuel users, we are committed to improving efficiency and addressing industry challenges to benefit our stakeholders across the maritime sector.

The joint venture will rely on data-driven insights for optimized decision-making and serve as a center of expertise for navigating evolving fuel regulations and technologies. Seascale Energy will initially represent close to 7.5 million metric tons in bunkering volume and will further its strong growth aspirations to increase scale.

Seascale Energy will be owned jointly and equally by Cargill and Hafnia. The new entity will be jointly governed and will operate under a dual-CEO structure (Olivier Josse, Cargill and Peter Grünwaldt, Hafnia). Business operations will commence in the second quarter of 2025 subject to pending regulatory approval.

Over 25 team members from Cargill and Hafnia will operate under Seascale Energy from Singapore, Geneva, Copenhagen, and Houston.

About Cargill: Cargill is committed to providing food, ingredients, agricultural solutions, and industrial products to nourish the world in a safe, responsible, and sustainable way. Sitting at the heart of the supply chain, we partner with farmers and customers to source, make and deliver products that are vital for living.

Our approximately 160,000 employees innovate with purpose, providing customers with life’s essentials so businesses can grow, communities prosper, and consumers live well. With 160 years of experience as a family company, we look ahead while remaining true to our values. We put people first. We reach higher. We do the right thing—today and for generations to come. For more information, visit Cargill.com and our News Center.

About Hafnia: Hafnia is a leading global tanker company specializing in the transportation of oil and chemical products. As one of the largest tanker owners and operators, Hafnia owns and commercially manages a modern fleet of over 200 vessels, ensuring safe, efficient, and responsible shipping solutions. Hafnia offers a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker desk.

With a commitment to operational excellence, sustainability, and innovation, Hafnia serves a diverse range of customers, including major national and international oil companies, chemical companies, as well as trading and utility companies. Headquartered in Singapore, Hafnia operates with a forward-thinking vision to set new industry standards, driven by its core values of Collaboration, Ambitious, Reliable, and Enduring.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250219375030/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 18:00:00 CEST | Press release

Initiation of the development of new oral triple combination tablets, aimed at improving adherence and outcomes in low-density lipoprotein cholesterol (LDL-C) management. Recent findings from MILOS and SANTORINI registries presented at ESC Congress 2025, highlight ongoing challenges in accurately assessing cardiovascular (CV) risk and helping patients reach LDL-C targets.1-5 Furthermore, data from a four-country cohort of the MILOS study support the real-world effectiveness and safety of bempedoic acid in both sexes.6 Simulation using SANTORINI data reveals the potential of improved LDL-C goal attainment with tailored oral combination therapy of statins, ezetimibe and bempedoic acid, in line with the latest 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.7,8 Daiichi Sankyo has a long-standing commitment to easing treatment of cardiovascular disease (CVD) and exploring new treatment options that improve CVD outcomes and treatment adherence. Daiich

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 16:30:00 CEST | Press release

- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented as a Late-Breaking Abstract at the European Society of Cardiology Congress 2025 -- Zilebesiran Demonstrated Clinically Meaningful Reductions in Office Systolic Blood Pressure in Patients with Uncontrolled Hypertension and High Cardiovascular Risk at Month 3 Primary Endpoint, with Continuous Control Through Month 6 -- Zilebesiran Displayed Encouraging Safety When Combined with Two or More Antihypertensives -- Results Support Biannual Dosing Regimen and Inform Phase 3 Trial Design: Trial Expected to Initiate by Year-End 2025 -- Alnylam to Host Webcast Investor Event on August 30, 2025, at 1:00 pm ET (7:00 pm CEST) - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from t

Andersen Consulting styrker sine kompetencer inden for virksomhedstransformation med Fabric29.8.2025 17:01:00 CEST | Pressemeddelelse

Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Fabric, der er et strategisk designfirma, der arbejder med organisationer for at integrere bæredygtighed, forsyningskæder og menneske-centreret innovation på tværs af kultur og drift. Fabric blev grundlagt i Japan i 2021 og arbejder sammen med virksomheder og globale brands om at skabe regenerative forretningsmodeller sammen samt bæredygtige brandstrategier og fremtidssikrede produkter. Ved hjælp af strategiske designmetoder og designfilosofi skaber virksomheden indsigtsbaseret transformation på tværs af forsyningskæder, brand og HR. Fabric er kendt for sin systemtænkning og sit engagement i social og miljømæssig bæredygtighed og fremmer desuden digitale transformationsinitiativer, der integrerer bæredygtighed, humankapital og AI. "Fabric er skabt for at hjælpe virksomheder med at blomstre gennem regenerative relationer til mennesker, samfund og forbundne, levende systemer," sagde James Hollow, der er grundlægger a

Andersen Consulting tilføjer samarbejdsfirmaet Skribble29.8.2025 16:28:00 CEST | Pressemeddelelse

Andersen Consulting udvider sine kompetencer inden for strategi og virksomhedstransformation gennem en samarbejdsaftale med Skribble, der er et rådgivningsfirma inden for digital teknologi og branding, der hjælper virksomheder i Sydøstasien med innovation og driftsmæssig transformation. Skribble, der blev etableret i 2020, tilbyder en bred vifte af services, herunder brand- og kommunikationsstrategi, digital markedsføring, specialudvikling af teknologi, forandringsledelse og platformsløsninger. Virksomheden hjælper organisationer inden for ejendomme, forbrugsvarer, bankverdenen og den offentlige sektor ved at sikre, at strategi og eksekvering er tæt forbundet – med henblik på at levere integrerede løsninger inden for brand, performance og teknologi. Skribbe fokuserer på procesoptimering har kreative og tekniske kompetencer, der hjælper kunderne med at skabe forandringer og vækst. "Hos Skribble arbejder vi på at omsætte kreativ energi til strategiske resultater," sagde Chan Leong, CEO f

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 12:00:00 CEST | Press release

Study met its primary endpoint of overall response rate (ORR), demonstrating clinically meaningful responses in rare B-cell lymphoma with high unmet needBeOne to submit data to global regulatory authorities for their review and potential approval BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye